Premium
Intralesional Alpha 2b Recombinant Interferon for Basal Cell Carcinomas
Author(s) -
Boneschi V.,
Brambilla L.,
Chiappino G.,
Mozzanica N.,
Finzi A. F.
Publication year - 1991
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1991.tb03859.x
Subject(s) - medicine , apocrine , scars , basal cell carcinoma , basal cell epithelioma , dermatology , pathology , basal cell
Basal cell carcinoma (BCC) is a rather common skin neoplasm, particularly in white patients. It grows slowly, has a locally malignant behavior, and metas‐tases occur only exceptionally. It is considered to be derived from pluripotential epithelial cells that can partially differentiate towards adnexal structures and sebaceous, apocrine, and sometimes eccrine glands. Prolonged exposure to the sun, a fair and freckled complexion, x‐rays, burn scars, and arsenic by mouth are all predisposing factors for basal cell epithelioma. The face and the trunk are the parts most often affected. Some patients, especially those with a fair complexion, may have dozens of BCCs at one time.